RXO RXO, Inc.

NYSE rxo.com


$ 10.48 $ -0.48 (-4.38 %)    

Thursday, 20-Nov-2025 15:57:58 EST
QQQ $ 585.57 $ -14.20 (-2.37 %)
DIA $ 458.11 $ -3.66 (-0.79 %)
SPY $ 652.49 $ -10.10 (-1.52 %)
TLT $ 89.25 $ 0.35 (0.39 %)
GLD $ 374.56 $ -0.11 (-0.03 %)
$ 10.48
$ 11.24
$ 10.46 x 41
$ 10.46 x 301
$ 10.45 - $ 11.24
$ 10.43 - $ 31.11
1,677,659
na
1.72B
$ 1.52
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-06-2025 09-30-2025 10-Q
2 08-07-2025 06-30-2025 10-Q
3 05-07-2025 03-31-2025 10-Q
4 02-27-2025 12-31-2024 10-K
5 11-07-2024 09-30-2024 10-Q
6 08-07-2024 06-30-2024 10-Q
7 05-07-2024 03-31-2024 10-Q
8 02-13-2024 12-31-2023 10-K
9 11-07-2023 09-30-2023 10-Q
10 08-02-2023 06-30-2023 10-Q
11 05-03-2023 03-31-2023 10-Q
12 02-24-2023 12-31-2022 10-K
13 11-30-2022 09-30-2022 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 wolfe-research-upgrades-rxo-to-peer-perform

Wolfe Research analyst Jacob Lacks upgrades RXO (NYSE:RXO) from Underperform to Peer Perform.

 morgan-stanley-upgrades-rxo-to-overweight-announces-19-price-target

Morgan Stanley analyst Ravi Shanker upgrades RXO (NYSE:RXO) from Equal-Weight to Overweight and announces $19 price target.

 ubs-maintains-neutral-on-rxo-lowers-price-target-to-15

UBS analyst Thomas Wadewitz maintains RXO (NYSE:RXO) with a Neutral and lowers the price target from $17 to $15.

 truist-securities-maintains-buy-on-rxo-lowers-price-target-to-20

Truist Securities analyst Lucas Servera maintains RXO (NYSE:RXO) with a Buy and lowers the price target from $22 to $20.

 barclays-maintains-overweight-on-rxo-lowers-price-target-to-15

Barclays analyst Brandon Oglenski maintains RXO (NYSE:RXO) with a Overweight and lowers the price target from $17 to $15.

 susquehanna-maintains-negative-on-rxo-lowers-price-target-to-10

Susquehanna analyst Bascome Majors maintains RXO (NYSE:RXO) with a Negative and lowers the price target from $11 to $10.

 rxo-q3-adj-eps-001-misses-004-estimate-sales-1421b-miss-1433b-estimate

RXO (NYSE:RXO) reported quarterly earnings of $0.01 per share which missed the analyst consensus estimate of $0.04 by 72.22 per...

 stifel-maintains-hold-on-rxo-raises-price-target-to-17

Stifel analyst J. Bruce Chan maintains RXO (NYSE:RXO) with a Hold and raises the price target from $14 to $17.

 goldman-sachs-maintains-neutral-on-rxo-lowers-price-target-to-15

Goldman Sachs analyst Jordan Alliger maintains RXO (NYSE:RXO) with a Neutral and lowers the price target from $17 to $15.

 jp-morgan-maintains-underweight-on-rxo-raises-price-target-to-16

JP Morgan analyst Brian Ossenbeck maintains RXO (NYSE:RXO) with a Underweight and raises the price target from $15 to $16.

 ubs-maintains-neutral-on-rxo-raises-price-target-to-17

UBS analyst Thomas Wadewitz maintains RXO (NYSE:RXO) with a Neutral and raises the price target from $15 to $17.

 barclays-maintains-overweight-on-rxo-lowers-price-target-to-17

Barclays analyst Brandon Oglenski maintains RXO (NYSE:RXO) with a Overweight and lowers the price target from $18 to $17.

 ubs-maintains-neutral-on-rxo-raises-price-target-to-15

UBS analyst Thomas Wadewitz maintains RXO (NYSE:RXO) with a Neutral and raises the price target from $14 to $15.

 rxo-expects-q3r-2025-adjusted-ebitda-to-be-between-33m-and-43m

Third-Quarter OutlookRXO expects third-quarter 2025 adjusted EBITDA to be between $33 million and $43 million.In Brokerage, the...

 rxo-q2-adj-eps-004-beats-003-estimate-sales-142b-miss-145b-estimate

RXO (NYSE:RXO) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $0.03 by 53.85 perce...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION